It has been documented over the past decade that interaction of CD200 with its receptor(s), CD200R(s) leads to attenuation of a variety of immune responses, resulting in, as will be discussed in more detail below, prolongation of survival of transplanted allografts [5], as well as, in some instances, decreased resistance to tumor growth. The gene discussed is CD200; the disease is neoplasm.